● Recruiting

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

Condition: Relapsing Multiple Sclerosis (RMS) · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants160

Who can joinAll sexes, 18 Years to 55 Years

Healthy volunteersNo

About this study

This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (15)

Novartis Investigative Site	Athens, Attica, Greece	Recruiting
Novartis Investigative Site	Athens, GR, Greece	Recruiting
Novartis Investigative Site	Alexandroupoli, Greece	Recruiting
Novartis Investigative Site	Athens, Greece	Recruiting
Novartis Investigative Site	Athens, Greece	Recruiting
Novartis Investigative Site	Athens, Greece	Recruiting
Novartis Investigative Site	Athens, Greece	Withdrawn
Novartis Investigative Site	Athens, Greece	Recruiting
Novartis Investigative Site	Chaïdári, Greece	Recruiting
Novartis Investigative Site	Crete Heraklion, Greece	Recruiting
Novartis Investigative Site	Ioannina, Greece	Recruiting
Novartis Investigative Site	Larissa, Greece	Recruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06486779